Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver ...
Le Lézard

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Inc. ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported ...